La bourse est fermée
  • CAC 40

    6 739,73
    -336,14 (-4,75 %)
     
  • Euro Stoxx 50

    4 089,58
    -203,66 (-4,74 %)
     
  • Dow Jones

    34 899,34
    -905,04 (-2,53 %)
     
  • EUR/USD

    1,1320
    +0,0108 (+0,96 %)
     
  • Gold future

    1 785,50
    +1,20 (+0,07 %)
     
  • BTC-EUR

    47 852,50
    -4 759,52 (-9,05 %)
     
  • CMC Crypto 200

    1 365,60
    -89,82 (-6,17 %)
     
  • Pétrole WTI

    68,15
    -10,24 (-13,06 %)
     
  • DAX

    15 257,04
    -660,94 (-4,15 %)
     
  • FTSE 100

    7 044,03
    -266,34 (-3,64 %)
     
  • Nasdaq

    15 491,66
    -353,57 (-2,23 %)
     
  • S&P 500

    4 594,62
    -106,84 (-2,27 %)
     
  • Nikkei 225

    28 751,62
    -747,66 (-2,53 %)
     
  • HANG SENG

    24 080,52
    -659,64 (-2,67 %)
     
  • GBP/USD

    1,3338
    +0,0018 (+0,14 %)
     

SAVA LAWSUIT FILED: Jakubowitz Law Pursues Claims on Behalf of Cassava Sciences, Inc. Shareholders

·1 min de lecture

New York, New York--(Newsfile Corp. - September 14, 2021) - Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Cassava Sciences, Inc. (NASDAQ: SAVA).

CLICK HERE FOR MORE DETAILS:
https://claimyourloss.com/securities/cassava-sciences-inc-loss-submission-form/?id=19609&from=5

Affected shareholders purchased shares of SAVA between February 2, 2021 and August 24, 2021

Shareholders interested in representing the class of wronged shareholders have until October 26, 2021 to petition the court. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

According to a filed complaint, Cassava Sciences, Inc. issued materially false and/or misleading statements and/or failed to disclose that: (a) the quality and integrity of the scientific data supporting Cassava's claims for simufilam's, a small molecule drug designed to treat Alzheimer's disease, efficacy had been overstated; (b) the scientific data supporting Cassava's claims for simufilam's efficacy were biased; and (c) as a result of the foregoing, Defendants' positive statements during the Class Period about the Company's business metrics and financial prospects and the likelihood of Food and Drug Administration approval were false and misleading and/or lacked a reasonable basis.

Jakubowitz Law is vigorous in pursuit of justice for shareholders who have been the victim of securities fraud. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
JAKUBOWITZ LAW
1140 Avenue of the Americas
9th Floor
New York, New York 10036
T: (212) 867-4490
F: (212) 537-5887

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/96594

Notre objectif est de créer un endroit sûr et engageant pour que les utilisateurs communiquent entre eux en fonction de leurs centres d’intérêt et de leurs passions. Afin d'améliorer l’expérience dans notre communauté, nous suspendons temporairement les commentaires d'articles